1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
Endometriosis Drug Forecasts and R&D 2016-2026

Endometriosis Drug Forecasts and R&D 2016-2026

  • February 2016
  • 142 pages
  • ID: 3744865
  • Format: PDF
  • Visiongain


Table of Contents

Report Details

Endometriosis Medicines – Your 2016 Guide to Sales Potentials of that Rising, Underserved Female Health Market
What does the future hold for treating endometriosis, a common disease? Our new analysis forecasts sales of drugs treating that menstrual cycle disorder. Visiongain’s report gives predictions to 2026 at overall world market, product and national level.

Avoid falling behind in data or losing influence. Instead discover what progress, opportunities and increasing revenues endometrial therapies face. There you also explore trends, results, R&D and events, assessing commercial prospects.

Read on, then, to explore endometriosis treatments, including hormonal therapy. See below what future revenue that expanding pharmaceuticals market could generate.

Forecasts and other analysis to benefit your research, assessments, plans and decisions
10% of women worldwide have endometriosis, giving high, rising demand for those medicines. New drugs appear and promising candidates reach clinical trials. Discover, from 2016, what revenues and other progress are possible in that expanding market.

Besides sales forecasting to 2026, our survey shows recent results, growth rates and market shares. There you find original analysis. You also assess research and development. The study gives 53 tables, 61 charts and a research interview.

Our report’s purpose is to help your research, analyses and decisions on the endometriosis drugs industry and market. Our work also benefits your authority and reputation for commercial insight, helping you compete and succeed.

The following sections explain how our new investigation benefits your work.

Predictions of drug sales – what is possible for those gynaecological medicines?
How will endometriosis medicines perform from 2015 to 2026 at world level? Our study forecasts revenues of these five brands:
- Lupron
- Eligard
- Zoladex
- Depo-Provera
- Visanne.

Our analysis shows how products can compete and succeed. There you investigate trends, exploring challenges, changes and opportunities. See what is possible.

Discover what the future holds for endometriosis drugs and their developers, producers and marketers.

Endometriosis Drug Forecasts and R&D 2016-2026: Revenues of that Expanding Market for Treating a Prevalent Women’s Reproductive System Disorder

Endometriosis R&D holds high potential – explore advances, assessing prospects
That therapeutic segment holds much promising research and development. The new gonadotropin-releasing hormone (GnRH) antagonist approach to treat endometriosis may take over from the present GnRH agonist drugs, our study notes.

There exists great scope for new and improved medicines, benefiting pharma companies, healthcare providers and patients. Explore, from 2016, what is possible, staying ahead in knowledge to benefit your work.

Our report also shows you geographical sales predictions.

National markets – what is possible for those gynaecological drug revenues?
Advances in biopharma expand the range and use of endometriosis-treating drugs. Our study shows you individual revenue forecasts to 2026 for 11 national markets:
- US
- Japan
- Germany, France, Italy, Spain, UK (EU5)
- China, Brazil, India, Russia (BRIC).

Endometriosis Drug Forecasts and R&D 2016-2026: Revenues of that Expanding Market for Treating a Prevalent Women’s Reproductive System Disorder

That way you assess countries and regions with highest revenues and potential sales growth. See what is possible, from 2016, in developed and developing countries.

That market gains momentum from rising disease prevalence, new and improved drugs and other forces stimulating treatment demand in that under-served market.

Endometriosis Drug Forecasts and R&D 2016-2026: Revenues of that Expanding Market for Treating a Prevalent Women’s Reproductive System Disorder

Influences, events and changes affecting companies treating endometriosis
Explore issues affecting that market, including these forces:
- Incidence and prevalence of that disorder, an often overlooked condition
- Raising disease awareness and overcoming reimbursement challenges
- Improving diagnosis and treatment of endometriosis – new therapies controlling hormones responsible for the build-up of endometrial tissue
- Hormone therapy, pain relievers (e.g. NSAIDs), contraceptives, medical devices and surgical options.

And gain insight on these developments, among others:
- Prospects for leading and emerging national markets – what the future holds for treating those vast patient populations
- Oral drug delivery for endometriosis – new therapies and novel drug candidates extend therapeutic and commercial potentials of that market
- Industry collaborations and R&D activities that stimulate progress.

In our report you also gain SWOT and PEST analysis, assessing what drives and restrains that expanding female health market.

That way you discover what is possible for leading pharma companies and specialists. Why miss out? Instead explore what the future holds for treating endometriosis, seeing the gains possible.

Leading companies and overall 2020 market value – what revenues are possible?
Our work predicts the world market for those drugs will reach $1.92 billion in 2020. That market will expand from 2016 to 2026. With our analysis you discover how high sales can go, seeing what is possible for those drug companies.

That way you assess what organisations hold most potential. Those companies include these organisations:
- AbbVie
- Pfizer
- Bayer HealthCare
- AstraZeneca
- Astellas
- Takeda.

Discover what the future holds for participants in that industry, exploring what they do, as well as their commercial potentials.

6 ways Endometriosis Drug Forecasts and R&D 2016-2026 helps your work
Our new investigation benefits your work in these six main ways, helping you stay ahead in knowledge and benefit your authority:
- Revenues for endometriosis drugs at overall world level to 2026 – assess scope for investments, developments, production and marketing
- Leading products’ sales to 2026 – discover predicted revenues of 5 prominent drugs, seeing how those medicines can compete and succeed
- National market forecasting to 2026 for 11 leading countries – explore the best regions for treatment demand, sales and revenue expansion
- Research and development – see progress, trends and prospects in that gynaecological R&D, assessing opportunities and possibilities
- Leading companies, news and opinion – examine participants in that rising market, gaining insight to help you stay ahead and succeed
- Analysis of what stimulates and restrains that market – assess challenges and strengths, helping you compete and gain advantages.

That analysis, by our in-house team in the UK, gives knowledge to benefit your research, plans, decisions and proposals. It shows data you find nowhere else.

Predictions for that female reproductive disorder – benefit your reputation for insight
With our independent study you assess products, companies, progress and possibilities for that female reproductive medicine. There discover the best commercial opportunities, as well as ways to help patients. See what is possible.

Having our analysis means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how to save time and effort, also benefiting your plans, decisions, presentations, proposals and influence.

Try that study, staying ahead. Our investigation shows you data, trends, opportunities and forecasts for that large, expanding female healthcare market. So avoid missing out – please get our new report here now.

Please note: This report is accessed through a password system. Single user (non-printable) and departmental licenses expires after 12 month period.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Elderly Nutrition Market Research Report by Type, by Application, by Distribution - United States Forecast to 2025 - Cumulative Impact of COVID-19

  • $ 2249
  • January 2021
  • 76 pages

Elderly Nutrition Market Research Report by Type (Antioxidants, Fibers, Iron, Lipids, and Minerals), by Application (Cancer, Cancer, Diabetes, Obesity, and Renal Failure), by Distribution - United States ...

  • United States
  • Infectious Disease
  • Genitourinary System Disease
  • Industry analysis


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on